The oral, small molecule inhibitor, PC14586, was administered in patients with advanced solid tumors with p53 Y220C mutation, including several breast cancer patients, as part of PMV Pharmaceuticals' Phase I/II clinical trial (NCT04585750). Here, TP53 is linked to breast carcinoma.